Orphan Drug Market Outlook to 2017
Orphan Drug Market Outlook to 2017
$3,000.00
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition. One of the sectors often cited as an opportunity for this is orphan diseases, where companies are provided incentives to develop drugs for these rare disorders which might otherwise be less commercially viable. The biggest and most pertinent benefit is clearly the guaranteed 7-year exclusivity period. Unsurprisingly then, Big Pharma has bought into orphan drugs in a major way, most notably Sanofi with its acquisition of Genzyme.
Indeed, Big Pharma now has the lion’s share of the orphan drugs market, as 77% of approved orphan drug sales in 2011 are derived from Big Pharma players. The implications of this are two-fold: in recent years, Big Pharma has been shifting away from the primary care blockbuster model while placing greater focus on specialty sectors, and personalized medicines targeting smaller patient populations with high value drugs. Consequently, many established companies have turned to deal-making activity with specialist players in an effort to secure promising pipeline candidates.
Table of Contents
5 EXECUTIVE SUMMARY
5 Scope of Datamonitor’s coverage of the orphan drug sector
7 Key findings
8 Definition of an orphan drug
8 Orphan drug market analysis, 2011–17
9 Orphan drug key companies
11 MARKET ANALYSIS
11 Key findings
11 Introduction
12 Orphan drug market size, 2005–17
32 COMPANY ANALYSIS
32 Key findings
33 Introduction
34 Novartis
36 Johnson & Johnson
38 Sanofi
40 Pfizer
42 AstraZeneca
43 Celgene
45 Allergan
46 Shire
48 UCB
49 Alexion
49 BioMarin
51 NPS Pharmaceuticals
52 Vertex
54 APPENDIX
54 References
55 Exchange rates
List of Figures
8 Figure 1: Orphan drug sales, by peer set ($m), 2011–17
10 Figure 2: Net orphan drug sales difference, by company ($m), 2011–17
12 Figure 3: Orphan drug market size ($m), 2005–17
21 Figure 4: Orphan drug sales, by therapy area ($m), 2011–17
24 Figure 5: Orphan drug sales, by molecule type ($m), 2011–17
25 Figure 6: Orphan drug sales, by peer set ($m), 2011–17
27 Figure 7: Net orphan drug sales difference, by company ($m), 2011–17
LIST OF TABLES
5 Table 1: Datamonitor’s orphan drug market company coverage
15 Table 2: Top 20 brands with an orphan drug approval by the FDA
18 Table 3: Orphan drugs therapy area sales ($m), 2011–17
23 Table 4: Orphan drug sales, by molecule type ($m), 2011–17
29 Table 5: Key orphan disease players as acquisition targets for major pharma companies
33 Table 6: The leading pharmaceutical companies in the orphan drug arena
55 Table 7: Exchange rates, 2012
Table 1: Datamonitor’s orphan drug market company coverage
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Big Pharma Outlook 2015 
Sign up to the